



**Supplemental figure 1. Validation of custom anti-hSR-BI and anti-hSR-BII antibodies.** Western blot analyses of cell lysates from HeLa cell lines: wild type (lane 1) and overexpressing hSR-BI (lane 2) or hSR-BII tgn (lane 3). hSR-BI and hSR-BII protein expression was detected by using either anti-human SR-BI and anti-human SR-BII custom antibodies (against specific peptides from C-terminal domains) or anti-human SR-BI/BII antibody (against 104-294 amino acid peptide from the extracellular loop, BD Biosciences). mSR-BI expression was also detected by anti-SR-BI antibody (against C-terminal 450-509 amino acid peptide, Novus Biologicals). Protein expression of  $\beta$ -actin was measured as the loading control.



**Supplemental figure 2. Neutralization and clearance of LPS in sera from WT, hSR-BI and hSR-BII transgenic mice.**

A. Activation of TLR4/NF- $\kappa$ B in HEK-Blue cells by LPS (0.5 ng/ml, 18hrs) in the presence and absence of 5% serum from WT, hSR-BI and hSR-BII transgenic mice. Data presented as means  $\pm$  SD (n=5 per group with duplicate measurements). \* P<0.05, \*\* P<0.01 vs sample w/o serum. Insert: Plasma HDL content of WT, hSR-BI and hSR-BII transgenic mice assessed by the apoA-I immunoblotting assay using anti-mouse apoA-I polyclonal antibody. A representative immunoblot (n=4 in each group) is shown. B. Activation of TLR4/NF- $\kappa$ B in HEK-Blue cells by 1% serum (during an 18h incubation period) obtained from WT, hSR-BI and hSR-BII transgenic mice following a 6h challenge with LPS (1mg/kg, i.p.). Data presented as means  $\pm$  SD (n=7-9 per group with duplicate measurements).



**Supplemental figure 3. LPS-induced pro-inflammatory cytokine responses in BMDM from WT, hSR-BI and hSR-BII transgenic mice.** BMDM were treated with LPS (1 $\mu$ g/ml) in 1% FBS-containing media for 0, 3, 6 and 18 hours. A. (IL-6) and B. (CXCL1). The cells were harvested and processed for cytokine mRNA quantification by qRT-PCR analysis. GAPDH mRNA served as the internal normalization control, and the expression level of each cytokine measured at 0 hrs time point was set as 1. C. (IL-6) and D. (CXCL1). Media were collected at different time points and assayed for target cytokine levels by ELISA.\* P<0.05, \*\* P<0.01 vs WT LPS-treated cells. Insert: Western blot analysis of BMDM from WT (lanes 1 and 3), hSR-BI tgn (lane 2) and hSR-BII tgn (lane 4) mice. The expression of hSR-BI and mSR-BI expression was detected utilizing an anti-SR-BI antibody (against C-terminal 450-509 amino acid peptide, Novus Biologicals, cat. # NB400-101) and hSR-BII protein was detected using custom antibody against C-terminal domain of human SR-BII. Protein expression of  $\beta$ -actin was measured as the loading control.